Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 17/20 | 1.00 |
| ▸ | MAPK12 | P53778 | 17/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 17/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 17/20 | 1.00 |
| ▸ | RAF1 | P04049 | 12/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 1/20 | 1.00 |
| ▸ | GCGR | P47871 | 4/20 | 0.82 |
| ▸ | BRAF | P15056 | 3/20 | 0.82 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.82 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2949385 | 1.00 | MAPK13 (1.00) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL20710613 | 0.93 | MAPK13 (0.86) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL5921859 | 0.91 | MAPK13 (1.00) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL2650068 | 0.91 | MAPK13 (1.00) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL28486758 | 0.91 | MAPK14 (1.00) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL6469877 | 0.91 | MAPK14 (1.00) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL4552316 | 0.91 | MAPK14 (1.00) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL6469543 | 0.91 | MAPK13 (1.00) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL6469111 | 0.91 | MAPK13 (1.00) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL9195042 | 0.91 | MAPK14 (1.00) | MAPK13MAPK12MAPK11MAPK14RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030064997-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2003-04-03 | — | — | US | claimed |
| US-10865384-B2 | 2,4,5-tri-substituted azole-based casein kinase 1 inhibitors as inducers for cardiomyogenesis | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-12-15 | — | — | US | disclosed |
| US-20170166867-A1 | 2,4,5-TRI-SUBSTITUTED AZOLE-BASED CASEIN KINASE 1 INHIBITORS AS INDUCERS FOR CARDIOMYOGENESIS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-06-15 | — | — | US | disclosed |
| US-20170166867-A1 | 2,4,5-TRI-SUBSTITUTED AZOLE-BASED CASEIN KINASE 1 INHIBITORS AS INDUCERS FOR CARDIOMYOGENESIS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-06-15 | — | — | US | disclosed |
| US-7826979-B2 | Method of modeling complex formation between a query ligan and a target molecule | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-02 | — | — | US | disclosed |
| US-7826979-B2 | Method of modeling complex formation between a query ligan and a target molecule | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-02 | — | — | US | disclosed |
| US-6645989-B2 | Antiinflammatory agents | SMITHKLINE BEECHAM CORPORATION | 2003-11-11 | — | — | US | disclosed |
| US-20030064997-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2003-04-03 | — | — | US | disclosed |
| US-6268370-B1 | CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION | 2001-07-31 | — | — | US | disclosed |
| US-5916891-A | CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-06-29 | — | — | US | disclosed |
| US-5656644-A | CYTOKINE SUPPRESSORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-08-12 | — | — | US | disclosed |
| WO-1995003297-A1 | IMIDAZOLES FOR TREATING CYTOKINE MEDIATED DISEASE | SMITHKLINE BEECHAM CORPORATION (US) | 1995-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10865384-B2 | 2,4,5-tri-substituted azole-based casein kinase 1 inhibitors as inducers for cardiomyogenesis | CSNK1A1, CSNK1G1, CSNK2A1 | MAPK13 234/4885MAPK12 366/4885MAPK11 372/4885 |
| US-20030064997-A1 | Novel compounds | BRD4, BRDT, HDAC6 | MAPK13 2219/4885MAPK12 3250/4885MAPK11 2198/4885 |
| US-20170166867-A1 | 2,4,5-TRI-SUBSTITUTED AZOLE-BASED CASEIN KINASE 1 INHIBITORS AS INDUCERS FOR CARDIOMYOGENESIS | CSNK1A1, CSNK1G1, CSNK2A1 | MAPK13 234/4885MAPK12 366/4885MAPK11 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.